🚀 VC round data is live in beta, check it out!
Viking Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Viking Therapeutics and similar public comparables like Shijiazhuang Yiling, Tianjin Pharma, Bayer SA, Hualan Biological Engineering and more.
Viking Therapeutics Overview
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Founded
2012
HQ
Employees
53
Website
Sectors
Financials (LTM)
EV
$3B
Viking Therapeutics Financials
Viking Therapeutics reported last 12-month revenue of — and negative EBITDA of ($424M).
In the same LTM period, Viking Therapeutics generated — in gross profit, ($424M) in EBITDA losses, and had net loss of ($393M).
Revenue (LTM)
Viking Therapeutics P&L
In the most recent fiscal year, Viking Therapeutics reported revenue of — and EBITDA of ($381M).
Viking Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($424M) | XXX | ($381M) | XXX | XXX | XXX |
| Net Profit | ($393M) | XXX | ($359M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Viking Therapeutics Stock Performance
Viking Therapeutics has current market cap of $4B, and enterprise value of $3B.
Market Cap Evolution
Viking Therapeutics' stock price is $35.20.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $4B | 0.0% | XXX | XXX | XXX | $-3.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialViking Therapeutics Valuation Multiples
Viking Therapeutics trades at (8.0x) EV/EBITDA.
EV / Revenue (LTM)
Viking Therapeutics Financial Valuation Multiples
As of April 19, 2026, Viking Therapeutics has market cap of $4B and EV of $3B.
Equity research analysts estimate Viking Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Viking Therapeutics has a P/E ratio of (10.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/EBITDA | (8.0x) | XXX | (8.9x) | XXX | XXX | XXX |
| EV/EBIT | (7.8x) | XXX | (8.6x) | XXX | XXX | XXX |
| P/E | (10.4x) | XXX | (11.4x) | XXX | XXX | XXX |
| EV/FCF | (6.9x) | XXX | (12.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Viking Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Viking Therapeutics Margins & Growth Rates
Viking Therapeutics' revenue in the last fiscal year grew by —.
Viking Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $7.4M for the same period.
Viking Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 32% | XXX | 38% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $7.4M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Viking Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Viking Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Shijiazhuang Yiling | XXX | XXX | XXX | XXX | XXX | XXX |
| Tianjin Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Bayer SA | XXX | XXX | XXX | XXX | XXX | XXX |
| Hualan Biological Engineering | XXX | XXX | XXX | XXX | XXX | XXX |
| Livzon Pharmaceutical Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Viking Therapeutics M&A Activity
Viking Therapeutics acquired XXX companies to date.
Last acquisition by Viking Therapeutics was on XXXXXXXX, XXXXX. Viking Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Viking Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialViking Therapeutics Investment Activity
Viking Therapeutics invested in XXX companies to date.
Viking Therapeutics made its latest investment on XXXXXXXX, XXXXX. Viking Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Viking Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Viking Therapeutics
| When was Viking Therapeutics founded? | Viking Therapeutics was founded in 2012. |
| Where is Viking Therapeutics headquartered? | Viking Therapeutics is headquartered in United States. |
| How many employees does Viking Therapeutics have? | As of today, Viking Therapeutics has over 53 employees. |
| Who is the CEO of Viking Therapeutics? | Viking Therapeutics' CEO is Brian Lian. |
| Is Viking Therapeutics publicly listed? | Yes, Viking Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Viking Therapeutics? | Viking Therapeutics trades under VKTX ticker. |
| When did Viking Therapeutics go public? | Viking Therapeutics went public in 2015. |
| Who are competitors of Viking Therapeutics? | Viking Therapeutics main competitors are Shijiazhuang Yiling, Tianjin Pharma, Bayer SA, Hualan Biological Engineering. |
| What is the current market cap of Viking Therapeutics? | Viking Therapeutics' current market cap is $4B. |
| Is Viking Therapeutics profitable? | No, Viking Therapeutics is not profitable. |
| What is the current EBITDA of Viking Therapeutics? | Viking Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Viking Therapeutics? | Current EBITDA multiple of Viking Therapeutics is (8.0x). |
| What is the current FCF of Viking Therapeutics? | Viking Therapeutics' last 12 months FCF is ($492M). |
| What is the current EV/FCF multiple of Viking Therapeutics? | Current FCF multiple of Viking Therapeutics is (6.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.